|
1
|
El Saghir NS, Khalil MK, Eid T, El Kinge
AR, Charafeddine M, Geara F, Seoud M and Shamseddine AI: Trends in
epidemiology and management of breast cancer in developing Arab
countries: a literature and registry analysis. Int J Surg.
5:225–233. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Tfayli A, Temraz S, Abou Mrad R and
Shamseddine A: Breast cancer in low- and middle-income countries:
an emerging and challenging epidemic. J Oncol. 2010:4906312010.
View Article : Google Scholar
|
|
3
|
Garcia-Closas M and Chanock S: Genetic
susceptibility loci for breast cancer by estrogen receptor status.
Clin Cancer Res. 14:8000–8009. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ma H, Bernstein L, Pike MC and Ursin G:
Reproductive factors and breast cancer risk according to joint
estrogen and progesterone receptor status: a meta-analysis of
epidemiological studies. Breast Cancer Res. 8:R432006. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Reeves GK, Beral V, Green J, Gathani T and
Bull D; Million Women Study Collaborators: Hormonal therapy for
menopause and breast-cancer risk by histological type: a cohort
study and meta-analysis. Lancet Oncol. 7:910–918. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Althuis MD, Fergenbaum JH, Garcia-Closas
M, Brinton LA, Madigan MP and Sherman ME: Etiology of hormone
receptor- defined breast cancer: a systematic review of the
literature. Cancer Epidemiol Biomarkers Prev. 13:1558–1568.
2004.PubMed/NCBI
|
|
7
|
Nakagawa M, Bando Y, Nagao T, Takai C,
Ohnishi T, Honda J, Moriya T, Izumi K, Takahashi M, Tangoku A, et
al: Among triple-negative breast cancers, HER2(0) breast cancer
shows a strong tendency to be basal-like compared with HER2(1+)
breast cancer: preliminary results. Breast Cancer. 19:54–59. 2012.
View Article : Google Scholar
|
|
8
|
Vaklavas C and Forero-Torres A: How do I
treat ‘triple-negative’ disease. Curr Treat Options Oncol.
12:369–388. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Berry DA, Cirrincione C, Henderson IC,
Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB,
Norton L, et al: Estrogen-receptor status and outcomes of modern
chemotherapy for patients with node-positive breast cancer. JAMA.
295:1658–1667. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Altman MB, Flynn MJ, Nishikawa RM, Chetty
IJ, Barton KN, Movsas B, Kim JH and Brown SL: The potential of
iodine for improving breast cancer diagnosis and treatment. Med
Hypotheses. 80:94–98. 2013. View Article : Google Scholar
|
|
11
|
Blows FM, Driver KE, Schmidt MK, Broeks A,
van Leeuwen FE, Wesseling J, Cheang MC, Gelmon K, Nielsen TO,
Blomqvist C, et al: Subtyping of breast cancer by
immunohistochemistry to investigate a relationship between subtype
and short and long term survival: a collaborative analysis of data
for 10,159 cases from 12 studies. PLoS Med. 7:e10002792010.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chu KC and Anderson WF: Rates for breast
cancer characteristics by estrogen and progesterone receptor status
in the major racial/ethnic groups. Breast Cancer Res Treat.
74:199–211. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Argiris A, Wang CX, Whalen SG and
DiGiovanna MP: Synergistic interactions between tamoxifen and
trastuzumab (Herceptin). Clin Cancer Res. 10:1409–1420. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Madsen MW and Briand P: Relationship
between tumorigenicity, in vitro invasiveness, and plasminogen
activator production of human breast cell lines. Eur J Cancer.
26:793–797. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Thompson EW, Paik S, Brünner N, Sommers
CL, Zugmaier G, Clarke R, Shima TB, Torri J, Donahue S, Lippman ME,
et al: Association of increased basement membrane invasiveness with
absence of estrogen receptor and expression of vimentin in human
breast cancer cell lines. J Cell Physiol. 150:534–544. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sommers CL, Byers SW, Thompson EW, Torri
JA and Gelmann EP: Differentiation state and invasiveness of human
breast cancer cell lines. Breast Cancer Res Treat. 31:325–335.
1994. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Skoog L, Humla S, Axelsson M, Frost M,
Norman A, Nordenskjöld B and Wallgren A: Estrogen receptor levels
and survival of breast cancer patients. A study on patients
participating in randomized trials of adjuvant therapy. Acta Oncol.
26:95–100. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sandelin K, Skoog L, Humla S and Farnebo
LO: Oestrogen, progesterone, and glucocorticoid receptors in normal
and neoplastic parathyroid glands. Eur J Surg. 158:467–472.
1992.PubMed/NCBI
|
|
19
|
Dohán O, De la Vieja A, Paroder V, Riedel
C, Artani M, Reed M, Ginter CS and Carrasco N: The sodium/iodide
symporter (NIS): characterization, regulation, and medical
significance. Endocr Rev. 24:48–77. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Chung JK: Sodium iodide symporter: its
role in nuclear medicine. J Nucl Med. 43:1188–1200. 2002.PubMed/NCBI
|
|
21
|
Tazebay UH, Wapnir IL, Levy O, Dohan O,
Zuckier LS, Zhao QH, Deng HF, Amenta PS, Fineberg S, Pestell RG, et
al: The mammary gland iodide transporter is expressed during
lactation and in breast cancer. Nat Med. 6:871–878. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mitchell AM, Manley SW, Morris JC, Powell
KA, Bergert ER and Mortimer RH: Sodium iodide symporter (NIS) gene
expression in human placenta. Placenta. 22:256–258. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wapnir IL, van de Rijn M, Nowels K, Amenta
PS, Walton K, Montgomery K, Greco RS, Dohán O and Carrasco N:
Immunohistochemical profile of the sodium/iodide symporter in
thyroid, breast, and other carcinomas using high density tissue
microarrays and conventional sections. J Clin Endocrinol Metab.
88:1880–1888. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Upadhyay G, Singh R, Agarwal G, Mishra SK,
Pal L, Pradhan PK, Das BK and Godbole MM: Functional expression of
sodium iodide symporter (NIS) in human breast cancer tissue. Breast
Cancer Res Treat. 77:157–165. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Kogai T, Taki K and Brent GA: Enhancement
of sodium/iodide symporter expression in thyroid and breast cancer.
Endocr Relat Cancer. 13:797–826. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Mazzaferri EL: Carcinoma of the follicular
epithelium. The Thyroid: A Fundamental and Clinical Text. Braverman
LE and Utiger R: 8th. Lippincott Williams and Wilkins;
Philadelphia, PA: pp. 904–930. 2000
|
|
27
|
Dai G, Levy O and Carrasco N: Cloning and
characterization of the thyroid iodide transporter. Nature.
379:458–460. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Smanik PA, Liu Q, Furminger TL, Ryu K,
Xing S, Mazzaferri EL and Jhiang SM: Cloning of the human sodium
lodide symporter. Biochem Biophys Res Commun. 226:339–345. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paire A, Bernier-Valentin F, Selmi-Ruby S
and Rousset B: Characterization of the rat thyroid iodide
transporter using anti-peptide antibodies. Relationship between its
expression and activity. J Biol Chem. 272:18245–18249. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Caillou B, Troalen F, Baudin E, Talbot M,
Filetti S, Schlumberger M and Bidart JM:
Na+/I− symporter distribution in human
thyroid tissues: an immunohistochemical study. J Clin Endocrinol
Metab. 83:4102–4106. 1998.PubMed/NCBI
|
|
31
|
Carrasco N: Iodide transport in the
thyroid gland. Biochim Biophys Acta. 1154:65–82. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Shen DH, Kloos RT, Mazzaferri EL and Jhian
SM: Sodium iodide symporter in health and disease. Thyroid.
11:415–425. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kogai T, Schultz JJ, Johnson LS, Huang M
and Brent GA: Retinoic acid induces sodium/iodide symporter gene
expression and radioiodide uptake in the MCF-7 breast cancer cell
line. Proc Natl Acad Sci USA. 97:8519–8524. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Mandell RB, Mandell LZ and Link CJ Jr:
Radioisotope concentrator gene therapy using the sodium/iodide
symporter gene. Cancer Res. 59:661–668. 1999.PubMed/NCBI
|
|
35
|
Campa D, Barrdahl M, Tsilidis KK, Severi
G, Diver WR, Siddiq A, Chanock S, Hoover RN, Ziegler RG, Berg CD,
et al: A genome-wide ‘pleiotropy scan’ does not identify new
susceptibility loci for estrogen receptor negative breast cancer.
PLoS One. 9:e859552014. View Article : Google Scholar
|
|
36
|
Dwyer RM, Bergert ER, O’connor MK, Gendler
SJ and Morris JC: In vivo radioiodide imaging and treatment of
breast cancer xenografts after MUC1-driven expression of the sodium
iodide symporter. Clin Cancer Res. 11:1483–1489. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Boland A, Ricard M, Opolon P, Bidart JM,
Yeh P, Filetti S, Schlumberger M and Perricaudet M:
Adenovirus-mediated transfer of the thyroid sodium/iodide symporter
gene into tumors for a targeted radiotherapy. Cancer Res.
60:3484–3492. 2000.PubMed/NCBI
|
|
38
|
Kilbane MT, Ajjan RA, Weetman AP, Dwyer R,
McDermott EW, O’Higgins NJ and Smyth PP: Tissue iodine content and
serum-mediated 125I uptake-blocking activity in breast
cancer. J Clin Endocrinol Metab. 85:1245–1250. 2000.PubMed/NCBI
|
|
39
|
Zhang M, Guo R, Shi S, Miao Y, Zhang Y and
Li B: Baculovirus vector-mediated transfer of sodium iodide
symporter and plasminogen kringle 5 genes for tumor radioiodide
therapy. PLoS One. 9:e923262014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Spitzweg C, O’Connor MK, Bergert ER,
Tindall DJ, Young CY and Morris JC: Treatment of prostate cancer by
radioiodine therapy after tissue-specific expression of the sodium
iodide symporter. Cancer Res. 60:6526–6530. 2000.PubMed/NCBI
|
|
41
|
Scholz IV, Cengic N, Baker CH, Harrington
KJ, Maletz K, Bergert ER, Vile R, Göke B, Morris JC and Spitzweg C:
Radioiodine therapy of colon cancer following tissue-specific
sodium iodide symporter gene transfer. Gene Ther. 12:272–280. 2005.
View Article : Google Scholar
|
|
42
|
Cengic N, Baker CH, Schütz M, Göke B,
Morris JC and Spitzweg C: A novel therapeutic strategy for
medullary thyroid cancer based on radioiodine therapy following
tissue-specific sodium iodide symporter gene expression. J Clin
Endocrinol Metab. 90:4457–4464. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Knostman KA, Cho JY, Ryu KY, Lin X,
McCubrey JA, Hla T, Liu CH, Di Carlo E, Keri R, Zhang M, et al:
Signaling through 3′,5′-cyclic adenosine monophosphate and
phosphoinositide-3 kinase induces sodium/iodide symporter
expression in breast cancer. J Clin Endocrinol Metab. 89:5196–5203.
2004. View Article : Google Scholar : PubMed/NCBI
|
